《盈警》荣昌生物(09995.HK)估计全年亏损收窄至14.7亿人民币

阿斯达克财经
16 Jan

荣昌生物(09995.HK) 发盈警,预计2024年度净亏损约14.7亿人民币,较上年度减少4,100万人民币,减幅约3%。营业收入预计增加58%至17.15亿人民币。

过往派息
公布日期派息事项派息内容
2024/10/29第三季业绩无派息
2024/08/16中期业绩无派息
2024/04/26第一季业绩无派息
2024/03/27末期业绩无派息

年内,公司新药研发管线持续推进,多个创新药处于关键试验研究阶段,研发投入增加,同时泰它西普和维迪西妥单抗销售收入快速增长,产品毛利率持续增长,销售费用率明显下降。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-16 16:25。)
AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10